478 related articles for article (PubMed ID: 14608526)
1. Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits.
Weckler N; Leitzbach D; Kalinowski L; Malinski T; Busch AE; Linz W
J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):191-6. PubMed ID: 14608526
[TBL] [Abstract][Full Text] [Related]
2. Vasopeptidase inhibition normalizes blood pressure and restores endothelial function in renovascular hypertension.
Quaschning T; Hocher B; Ruhl S; Kraemer-Guth A; Tilgner J; Wanner C; Galle J
Kidney Blood Press Res; 2006; 29(6):351-9. PubMed ID: 17139187
[TBL] [Abstract][Full Text] [Related]
3. Vasopeptidase inhibition prevents target organ damage and improves survival in spontaneously hypertensive rats.
Linz W; Schäfer S; Afkham F; Gerl M; Schmidts HL; Rütten H
J Renin Angiotensin Aldosterone Syst; 2006 Sep; 7(3):155-61. PubMed ID: 17094052
[TBL] [Abstract][Full Text] [Related]
4. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits: II. Effect on regression of atherosclerosis and restoration of endothelial function.
Riezebos J; Vleeming W; Beems RB; van Amsterdam JG; Meijer GW; de Wildt DJ; Porsius AJ; Wemer J
J Cardiovasc Pharmacol; 1994 Mar; 23(3):424-31. PubMed ID: 7515986
[TBL] [Abstract][Full Text] [Related]
6. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits: I. Effect on progression of atherosclerosis and endothelial dysfunction.
Riezebos J; Vleeming W; Beems RB; van Amsterdam JG; Meijer GW; de Wildt DJ; Porsius AJ; Wemer J
J Cardiovasc Pharmacol; 1994 Mar; 23(3):415-23. PubMed ID: 7515985
[TBL] [Abstract][Full Text] [Related]
8. ACE inhibition promotes upregulation of endothelial progenitor cells and neoangiogenesis in cardiac pressure overload.
Müller P; Kazakov A; Jagoda P; Semenov A; Böhm M; Laufs U
Cardiovasc Res; 2009 Jul; 83(1):106-14. PubMed ID: 19380417
[TBL] [Abstract][Full Text] [Related]
9. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
[TBL] [Abstract][Full Text] [Related]
10. The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension.
Seccia TM; Belloni AS; Guidolin D; Sticchi D; Nussdorfer GG; Pessina AC; Rossi GP
J Hypertens; 2006 Jul; 24(7):1419-27. PubMed ID: 16794493
[TBL] [Abstract][Full Text] [Related]
11. Ramipril improves nitric oxide availability in hypertensive rats with failing hearts after myocardial infarction.
Linz W; Itter G; Dobrucki LW; Malinski T; Wiemer G
J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):180-5. PubMed ID: 14608524
[TBL] [Abstract][Full Text] [Related]
12. Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure.
Zhang X; Recchia FA; Bernstein R; Xu X; Nasjletti A; Hintze TH
J Pharmacol Exp Ther; 1999 Feb; 288(2):742-51. PubMed ID: 9918584
[TBL] [Abstract][Full Text] [Related]
13. Contribution of bradykinin to the cardiovascular effects of ramipril.
Linz W; Wiemer G; Schölkens BA
J Cardiovasc Pharmacol; 1993; 22 Suppl 9():S1-8. PubMed ID: 7514234
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits.
Oubiña MP; de las Heras N; Cediel E; Sanz-Rosa D; Aragoncillo P; Díaz C; Hernández G; Lahera V; Cachofeiro V
Clin Sci (Lond); 2003 Dec; 105(6):655-62. PubMed ID: 12848617
[TBL] [Abstract][Full Text] [Related]
15. [ACE inhibition and atherosclerosis in the animal model].
Becker RH
Z Kardiol; 1994; 83 Suppl 4():15-20. PubMed ID: 7856276
[TBL] [Abstract][Full Text] [Related]
16. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients.
Pasini AF; Garbin U; Nava MC; Stranieri C; Pellegrini M; Boccioletti V; Luchetta ML; Fabrizzi P; Lo Cascio V; Cominacini L
Am J Hypertens; 2007 Apr; 20(4):443-50. PubMed ID: 17386354
[TBL] [Abstract][Full Text] [Related]
17. [Effects of losartan, ramipril and their combination on left ventricular remodeling and function in spontaneous hypertensive rats].
Xu R; Zhang Y; Zhang M; Li XC; Cai H; Chen WQ; Zhu H; Ge ZM; Zhang W
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3199-204. PubMed ID: 16405840
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin converting enzyme inhibitors and atherosclerosis.
Andersson RG; Jacobsson L; Persson K
J Physiol Pharmacol; 1994 Mar; 45(1):13-25. PubMed ID: 8043902
[TBL] [Abstract][Full Text] [Related]
19. Effects of acute and chronic treatment with the sodium hydrogen exchanger 1 (NHE-1) inhibitor cariporide on myocardial infarct mass in rabbits with hypercholesterolaemia.
Jung O; Albus U; Lang HJ; Busch AE; Linz W
Basic Clin Pharmacol Toxicol; 2004 Jul; 95(1):24-30. PubMed ID: 15245573
[TBL] [Abstract][Full Text] [Related]
20. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
